1-16 of 16
imatinib mesylate
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs

Abdülkadir Erçalışkan, Duygu Seyhan Erdoğan, Ahmet Emre Eşkazan
Journal: Blood Advances
Blood Adv (2021) 5 (17): 3344–3353.
https://doi.org/10.1182/bloodadvances.2021004194
Published: 2021
Journal Articles

A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety

Clinical Trials & Observations
Nobuko Hijiya, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco Bautista, Stéphane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frédéric Millot, Briana Patterson, Jill Samis, Paola Aimone, Alex Allepuz, Ksenia Titorenko, Darintr Sosothikul
Journal: Blood Advances
Blood Adv (2021) 5 (14): 2925–2934.
https://doi.org/10.1182/bloodadvances.2020003759
Published: 2021
Includes: Supplemental data
Journal Articles

Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania

Clinical Trials & Observations Global Advances
Ahlam Nasser, Ally Hussein, Clara Chamba, Mbonea Yonazi, Rosemary Mushi, Anna Schuh, Lucio Luzzatto
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1403–1411.
https://doi.org/10.1182/bloodadvances.2020002973
Published: 2021
Includes: Supplemental data
Journal Articles

Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression

Clinical Trials & Observations
Richard E. Clark, Jane F. Apperley, Mhairi Copland, Silvia Cicconi
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1102–1109.
https://doi.org/10.1182/bloodadvances.2020003570
Published: 2021
Includes: Supplemental data
Journal Articles

Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission

Clinical Trials & Observations
Philippe Rousselot, Clémence Loiseau, Marc Delord, Jean Michel Cayuela, Marc Spentchian
Journal: Blood Advances
Blood Adv (2020) 4 (13): 3034–3040.
https://doi.org/10.1182/bloodadvances.2020001772
Published: 2020
Includes: Supplemental data
Journal Articles

First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis

Clinical Trials & Observations
Claudia Vener, Rita Banzi, Federico Ambrogi, Annalisa Ferrero, Giuseppe Saglio, Gabriella Pravettoni, Milena Sant
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2723–2735.
https://doi.org/10.1182/bloodadvances.2019001329
Published: 2020
Includes: Supplemental data
Journal Articles

A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia

Clinical Trials & Observations
Max Jan, Daniel E. Grinshpun, Julian A. Villalba, Paola Dal Cin, David B. Sykes, A. John Iafrate, Benjamin L. Ebert, Gabriela S. Hobbs, Valentina Nardi
Journal: Blood Advances
Blood Adv (2020) 4 (3): 445–448.
https://doi.org/10.1182/bloodadvances.2019001182
Published: 2020
Journal Articles

Treatment-free remission in FIP1L1-PDGFRA –positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation

Clinical Trials & Observations
Georgia Metzgeroth, Juliana Schwaab, Nicole Naumann, Mohamad Jawhar, Torsten Haferlach, Alice Fabarius, Andreas Hochhaus, Wolf-Karsten Hofmann, Nicholas C. P. Cross, Andreas Reiter
Journal: Blood Advances
Blood Adv (2020) 4 (3): 440–443.
https://doi.org/10.1182/bloodadvances.2019001111
Published: 2020
Journal Articles

Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation

Clinical Trials & Observations
Chihiro Yamamoto, Hirotomo Nakashima, Takashi Ikeda, Shin-ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Kiyomi Mashima, Takashi Nagayama, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Miyuki Sugimoto, Yuko Ishihara, Masahiro Ashizawa, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Shin-ichiro Fujiwara, Masuzu Ueda, Ken Ohmine, Kazuo Muroi, Yoshinobu Kanda
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3266–3277.
https://doi.org/10.1182/bloodadvances.2019000745
Published: 2019
Includes: Supplemental data
Journal Articles

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib

Clinical Trials & Observations
Chung H. Kok, David T. Yeung, Liu Lu, Dale B. Watkins, Tamara M. Leclercq, Phuong Dang, Verity A. Saunders, John Reynolds, Deborah L. White, Timothy P. Hughes
Journal: Blood Advances
Blood Adv (2019) 3 (10): 1610–1621.
https://doi.org/10.1182/bloodadvances.2019000195
Published: 2019
Includes: Supplemental data
Journal Articles

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Clinical Trials & Observations
Preetesh Jain, Hagop Kantarjian, Prajwal C. Boddu, Graciela M. Nogueras-González, Srdan Verstovsek, Guillermo Garcia-Manero, Gautam Borthakur, Koji Sasaki, Tapan M. Kadia, Princy Sam, Hycienth Ahaneku, Susan O’Brien, Zeev Estrov, Farhad Ravandi, Elias Jabbour, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2019) 3 (6): 851–861.
https://doi.org/10.1182/bloodadvances.2018025874
Published: 2019
Includes: Supplemental data
Journal Articles

Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI

Clinical Trials & Observations
Naranie Shanmuganathan, Susan Branford, Timothy P. Hughes, Devendra Hiwase
Journal: Blood Advances
Blood Adv (2019) 3 (3): 370–374.
https://doi.org/10.1182/bloodadvances.2018027516
Published: 2019
Includes: Supplemental data
Journal Articles

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation

Clinical Trials & Observations
Koichi Miyamura, Kazunori Ohnishi, Shigeki Ohtake, Noriko Usui, Chiaki Nakaseko, Hiroyuki Fujita, Shin Fujisawa, Toru Sakura, Hirokazu Okumura, Noriyoshi Iriyama, Nobuhiko Emi, Katsumichi Fujimaki, Sumihisa Honda, Yasushi Miyazaki, Tomoki Naoe
Journal: Blood Advances
Blood Adv (2019) 3 (3): 312–319.
https://doi.org/10.1182/bloodadvances.2018025981
Published: 2019
Includes: Supplemental data
Journal Articles

Imatinib is still recommended for frontline therapy for CML

Clinical Trials & Observations
Andrew Hantel, Richard A. Larson
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3648–3652.
https://doi.org/10.1182/bloodadvances.2018018614
Published: 2018
Journal Articles

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure

Clinical Trials & Observations
Justine E. Marum, David T. Yeung, Leanne Purins, John Reynolds, Wendy T. Parker, Doris Stangl, Paul P. S. Wang, David J. Price, Jonathan Tuke, Andreas W. Schreiber, Hamish S. Scott, Timothy P. Hughes, Susan Branford
Journal: Blood Advances
Blood Adv (2017) 1 (18): 1369–1381.
https://doi.org/10.1182/bloodadvances.2017006825
Published: 2017
Includes: Supplemental data
Journal Articles

The clinical spectrum of Erdheim-Chester disease: an observational cohort study

Clinical Trials & Observations
Juvianee I. Estrada-Veras, Kevin J. O’Brien, Louisa C. Boyd, Rahul H. Dave, Benjamin H. Durham, Liqiang Xi, Ashkan A. Malayeri, Marcus Y. Chen, Pamela J. Gardner, Jhonell R. Alvarado Enriquez, Nikeith Shah, Omar Abdel-Wahab, Bernadette R. Gochuico, Mark Raffeld, Elaine S. Jaffe, William A. Gahl
Journal: Blood Advances
Blood Adv (2017) 1 (6): 357–366.
https://doi.org/10.1182/bloodadvances.2016001784
Published: 2017
Includes: Supplemental data